Can earlier biomarker measurements explain a treatment effect on diabetes incidence? A robust comparison of five surrogate markers
Authors' conclusion
These data suggest that, of the five examined surrogate markers, glucose and HOMA-IR were the superior surrogate markers in terms of PTE, compared with 2-hour glucose, HbA1c, and TyG index.
Study context
- Population
- Diabetes Prevention Program participants
- Participants
- 1,023 vs 1,030
- Comparison
- Five surrogate markers (1-year change) in explaining the effect of lifestyle intervention vs placebo on T2D incidence
- Lifestyle interventionn = 1,023
- Placebon = 1,030reference
- Primary endpoint
- Proportion of treatment effect explained (PTE) on T2D incidence by 1-year change in HbA1c, fasting glucose, 2-hour postchallenge glucose, TyG index and HOMA-IR
- Follow-up
- 2, 3, and 4 years after treatment initiation
Methodological detailsRobust model-free estimate of PTE
- Robust model-free estimate of PTE
Primary result
As reported in the abstract
PTE by surrogate marker · 2 years
- PTE, fasting glucose (highest)
- 80.1%
- PTE, homeostatic model assessment of insulin resistance (HOMA-IR)
- 77.7%
- PTE, 2-hour glucose
- 76.2%
- PTE, hemoglobin A1c (HbA1c)
- 74.6%
- PTE, TyG index (smallest)
- 70.3%
Original publication
Can earlier biomarker measurements explain a treatment effect on diabetes incidence? A robust comparison of five surrogate markers. BMJ Open Diabetes Res Care. Published 31 October 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →